1. Aubrey Stoch, MD, Merck Inc.
  2. Aarash Bordbar, PhD, University of California San Diego
  3. Adrian Ray, Ph.D., Gilead Sciences Inc.
    Putting it All Together: Transporter Function in the Context of Organ Systems
  4. Amin Rostami-Hodjegan, PharmD, PhD, University of Manchester
    Physiologically Based Pharmaokinetic Modeling (PBPK)
  5. Angelean Hendrix, PhD, GlaxoSmithKline
    Requisite Hybrid Modeling: Mathematical Theory Applied to Systems Pharmacological Modeling
  6. Anne Heatherington, PhD, Pfizer
  7. Antonina Nikitich, MS, Institute for Systems Biology Moscow
  8. Aram Oganesian, PhD, Astex Pharmaceuticals
  9. Arthur Atkinson, Jr., MD, Northwestern University
  10. Ashley Slagle, MS, PhD, US Food and Drug Administration
    PRO ENDPOINTS IN ONCOLOGY TRIALS: A REGULATORY PERSPECTIVE
  11. Bert Lum, Pharm.D., Genentech
  12. Bing Wang, Ph.D., AstraZenica/MedImmune
  13. Brian Kirby, PhD, Gilead Sciences
    Sofosbuvir Initiates New Era in Treatment of Hepatitis C: A Cure for Hepatitis C on the Horizon
  14. Brian Schmidt, PhD, Bristol-Myers Squibb
  15. Bridgette Jones, MD, Children's Mercy Hospitals and Clinics
  16. Carl Peck, MD, University of California, San Francisco
    A Single Trial As Evidence of Effectiveness: History and Implementation
  17. Caroline Pike, PhD, Ascension
  18. Caroline Pike, PhD, Leadership & Organization Dynamics
  19. Catherine Sherwin, BSc(Hons), PhD, University of Utah School of Medicine
  20. Cathrine Leonowens, PhD, Parexel
    When the (Data) Glass is Half Full: Using Probabilistic Risk Analysis to Make Better Decisions
  21. Craig Hendrix, MD, Johns Hopkins University School of Medicine
  22. Dan Roden, MD, Vanderbilt University School of Medicine
    Phenomewide Association Studies, PheWAS, in Furthering Pharmacogenomic Discoveries
  23. Daniel Rosenbloom, PhD, Columbia University
    HIV Cure: How Can We Get There? Modeling Viral Dynamics, Drug Effects, and the Latent Reservoir to Devise Curative Strategies
  24. Daniel Rotroff, PhD, North Carolina State University
  25. Darrell Abernethy, MD, PhD, US Food and Drug Administration
    Effects of Aging Pathophysiology on Drug Disposition and Effect
  26. David Cook, PhD, Seres Health
  27. David Feigal, MD, MPH, NDA Partners LLC
    Clinical Trials in Drug Development: Thinking Quantitatively
  28. David Flockhart, MD, PhD, Indiana University School of Medicine
    Clinical Pharmacogenomics
  29. David Greenblatt, MD, Tufts University School of Medicine
    Pharmacokinetics
  30. David Hermann, PharmD, Certara USA, Inc.
  31. David Swinney, PhD, Institute for Rare and Neglected Diseases Drug Discovery
    Biochemical Mechanisms of Successful Drugs with Emphasis on Drug Characteristics
  32. Dhananjay Marathe, PhD, US Food and Drug Administration
    Biomarkers and Pharmacometrics in Drug Development: A Regulatory Perspective
  33. Dhanesh Gupta, M.D., Duke University School of Medicine
  34. Dionna Green, MD, US Food and Drug Administration
  35. Donald Mager, PharmD, PhD, University at Buffalo, SUNY
    Mechanistic Pharmacokinetic/Pharmacodynamic Models
  36. Donald Rubin, PhD, Harvard University
    Statistical Considerations for Evidence of Effectiveness
  37. Edmund Lee, MD, PhD, National University of Singapore
  38. Eleftheria Tsakalozou, PhD, University of North Carolina
  39. Eric Sobie, PhD, Icahn School of Medicine at Mount Sinai
    Exploiting Mathematical Models to Understand and Predict Individualized Arrhythmia Risk
  40. Evan Stein, MD, PhD, Metabolic & Atherosclerosis Research Center
    Novel Lipid Lowering Strategies and the Role of PCSK9
  41. Frederick Raal, FRCP, FRCPC, FCP(SA), Cert Endo, MMED, PhD, University of the Witwatersrand
  42. Ganesh Mugundu, M.Pharm, Ph.D, Pfizer
  43. Gary Gintant, PhD, Abbvie
    Mechanistic-Based In Vitro/In Silico Approaches to Assess Proarrhythmic Risk
  44. Georgios Vlasakakis, PhD, GlaxoSmithKline
  45. Gideon Koren, MD, FRCPC, The Hospital for Sick Children
    Drugs in Pregnancy: Treating the Mother, Protecting the Unborn
  46. Hans Westerhoff, PhD, University of Amsterdam and VU University Amsterdam and the University of Manchester
    Metabolomics
  47. Harma Ellens, PhD, GlaxoSmithKline
  48. Hiroshi Suzuki, PhD, University of Tokyo Hospital
    Systems Pharmacology Approach to Tyrosine Kinase Inhibitor Toxicity
  49. Hong Zhao, PhD, US Food and Drug Administration
    What are the Regulatory Expectations for Dose Selection of Biologics
  50. Indranil Bhattacharya, PhD, Pfizer
    What Clinical Pharmacology Aspects are “More Complex” with a Biologic?
  51. Issam Zineh, PharmD, MPH, US Food and Drug Administration
    Breakthrough Therapy Designation Driving Medical Innovation
  52. Jaap Mandema, PhD, Quantitative Solutions
    Utilizing Model Based Meta-Analysis to Inform Clinical Impact of PCSK9 Inhibitors
  53. Jack Cook, Ph.D., Pfizer
    INDUSTRIAL PERSPECTIVE: NTI CONSIDERATIONS IN ONGOING PRODUCT QUALITY
  54. James Gallo, PharmD, PhD, Icahn School of Medicine at Mount Sinai
    Integrating Systems Pharmacology and PBPK: Application to Oncology
  55. Jeffrey Aronson, DPhil, FRCP, University of Oxford
  56. Jianghong Fan, Ph.D., US Food and Drug Administration
  57. Jin Jin, Ph.D., Genentech
    Translational PK/PD and Dose Optimization for ADCs
  58. Jinzhong Liu, Ph.D. Candidate, Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine
  59. Jogarao Gobburu, PhD, MBA, University of Maryland
  60. John Brownstein, PhD, Children's Hospital Boston
    Digital Disease Detection: Current Capabilities and Future Directions in the Use of the Non-Traditional Data Sources for Public Health Surveillance and Rapid Detection of Emerging Infectious Diseases
  61. John Davis, Ph.D., Regeneron Pharmaceuticals
  62. John Gibbs, PhD, Amgen
    Translational and Clinical Pharmacology Development of Anti-PCSK9 Therapy: From Bench to Bedside
  63. John Wagner, MD, PhD, Takeda Pharmaceuticals
  64. Jon Lorsch, PhD, National Institutes of Health
  65. Joseph Fleishaker, PhD, Astellas
  66. Joshua Denny, MD, Vanderbilt University
    Electronic Medical Records to Evaluate Drug Effects
  67. Juergen Hahn, PhD, Rensselaer Polytechnic Institute
    Identifying and Validating Systems Pharmacology Models
  68. Julie Johnson, PharmD, University of Florida
  69. Junmei Cairns, PhD, Mayo Clinic
  70. Kapil Gadkar, PhD, Genentech
  71. Kathleen Giacomini, PhD, University of California, San Francisco
    Discovery of Endogenous Biomarkers for Transporters
  72. Kathleen Hillgren, PhD, Eli Lilly and Company
  73. Kathleen Uhl, MD, US Food and Drug Administration
    Effective Oral Presentations
  74. Keith Gottesdiener, MD, FACP, Rhythm Pharmaceuticals
  75. Kellie Reynolds, Pharm.D., US Food and Drug Administration
  76. Kelly Dooley, MD, PHD, Johns Hopkins University School of Medicine
  77. Kenneth Rockwood, BA, MPA, BMS, MD, FRCPC, Dalhousie University & Centre for Health Care of the Elderly
    William B. Abrams Award in Geriatric Clinical Pharmacology
  78. Kevin Krudys, PhD, US Food and Drug Administration
    Little Data, Big Decisions in Regulatory Review
  79. Kim Brouwer, PharmD, PhD, University of North Carolina at Chapel Hill
  80. Lanyan (Lucy) Fang, Ph.D., FDA
    Bioequivalence Standards for Narrow Therapeutic Index (NTI) Drugs: Are They Stringent Enough to Ensure Safety and Efficacy?
  81. Larissa Wenning, PhD, Merck & Co., Inc.
  82. Lei Zhang, PhD, US Food and Drug Administration
    When Should In Vivo Transporter-Mediated Drug-Drug Interaction Studies be Conducted? A Regulatory Perspective
  83. Leslie Benet, PhD, UCSF
    Translating In Vitro Transporter Studies into In Vivo Predictions: Successes, Challenges and Future Directions
  84. Lisa von Moltke, MD, FCP, Genzyme--a Sanofi Company
    Decoy: Sex is NOT the Most Important Polymorphism Determining Drug Exposure or Drug Response
  85. Lori Minasian, M.D., National Cancer Institute
    The Development and Utility of PRO Tools: The PRO-CTCAE Measurement System
  86. Maciej Zamek-Gliszczynski, PhD, GlaxoSmithKline, Inc.
    Interactions of Drug Metabolites with Transporters: Perspectives and Issues for Drug Development
  87. Malcolm Rowland, DSc, PhD, University of Manchester
  88. Manoranjenni Chetty, PhD, Simcyp
  89. Maria Posada, Ph.D., Eli Lilly and Company
  90. Mark Caulfield, MD, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry
    Personalizing Medicines through Drug Sequencing
  91. Martha Brumfield, PhD, Critical Path Institute
  92. Mary Relling, PharmD, St. Jude Children's Research Hospital
    Personalized Medicines Using Genomewide Approaches
  93. Mats Karlsson, Ph.D., Uppsala University
    Pharmacometrics of Tyrosine Kinase Inhibitor Adverse Drug Reactions
  94. Matthew Hutmacher, MS, A2PG
    Quantitative Approach for Study Design and Establishing Decision Criteria for High Uncertainty Scenarios
  95. Matthias Schwab, MD, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology
  96. Megan Gibbs, PhD, BscPharm, FCP, Amgen
  97. Meina Tang, PhD, Genentech Inc
    What Clinical Pharmacology Aspects are “Simpler” with a Biologic?
  98. Melina Kibbe, M.D., Northwestern University and the Jesse Brown VA Medical Center
    Porgy & Bess: Sex-Related Disparities in Basic and Translational Research
  99. Mengyao Li, M.S., Virginia Commonwealth University
  100. Michael Cohen-Walkowiez, M.D. Ph.D, Duke University School of Medicine
    Use of PK/PD Modeling to Aid in Classification of NTI Drugs
  101. Michael Levitt, PhD, Stanford University
  102. Michael Maitland, MD, PhD, University of Chicago Medical Center
    Placing the Fulcrum: Balancing the Benefits and Risks of Breakthrough Therapy Designation?
  103. Michael Williams, PhD, DSc, Feinberg School of Medicine
    THE EXPANDING UNIVERSE OF RECEPTORS AND RECEPTOR SIGNALING: HIERARCHICAL COMPLEXITY IN A REDUCTIONIST WORLD
  104. Michel Eichelbaum, MD, University of TŸbingen
    Of Broom, CYPs, SNPs and Other Things
  105. Michelle Rudek, Pharm. D., Ph.D., Sidney Kimmel Cancer Center at Johns Hopkins
    Drugs Used for Phenotyping in Clinical Pharmacology
  106. Mikko Niemi, MD, PhD, University of Helsinki
  107. Mohamed Shahin, BPharm, MSc., University of Florida
  108. Munir Pirmohamed, MD, PhD, University of Liverpool
    Genomewide Approaches to the Discovery of Drug Safety Biomarkers
  109. Myong-Jin Kim, PharmD, US Food and Drug Administration
    Milestones: Sex-Related Insights from Post-Marketing Data
  110. Neeraj Gupta, PhD, Takeda Pharmaceuticals
  111. Norman Stockbridge, MD, PhD, US Food and Drug Administration
    Regulatory Perspectives on TQT Studies and Alternative Approaches to Assess TdP Risk
  112. Pamela Flood, M.D., M,A,, Stanford University
    Birth of the Cool: Sex, Pain, Analgesics and Pregnancy
  113. Patricia Slattum, PharmD, PhD, Virginia Commonwealth University
    Henry W. Elliott Distinguished Service Award
  114. Paul Watkins, MD, The Hamner-University of North Carolina
    Why Good Drugs are Sometimes Bad for the Liver
  115. Paulien Ravenstijn, PhD, Janssen Research & Development
  116. Peter Honig, MD, MPH, Pfizer
  117. Piet van der Graaf, PhD, PharmD, Leiden Academic Centre for Drug Research (LACDR)
    Proof of Pharmacology: The Three Pillars of Survival Underpinning PoC Success
  118. Pravin Jadhav, PhD, MPH, Merck, Quantitative Pharmacology and Pharmacometrics
  119. Rada Savic, PharmD, PhD, University of California
    Systems Pharmacology Modeling to Predict Tuberculosis Treatment Response: Bug, Drug, Gene and Host Interactions
  120. Rahul Bakshi, PhD, Johns Hopkins University
    In Vitro System to Evaluate Pharmacokinetic/Pharmacodynamic Relationships for Anti-Malarial Drugs
  121. Raj Vuppalanchi, MD, IU Health University Hospital
    Hepatitis Therapy
  122. Rameshraja Palaparthy, PhD, Amgen, Inc
  123. Richard Lalonde, PharmD, Pfizer
  124. Richard Peck, MD, Roche Pharmaceutical Research and Early Development
  125. Rima Kaddurah-Daouk, PhD, Duke University Medical Center
    Pharmacometabolomics Enabling Tools for Systems Pharmacology
  126. Rob Knight, PhD, University of Colorado
    The Role of the Gut Microbiota in the Pathogenesis of Disease and Drug Response
  127. Robert Bies, PharmD, PhD, Indiana University
    Population Pharmacokinetics/Pharmacodynamics: Bayesian Approaches to Pharmacologic Data Analysis
  128. Robert Hemmings, PhD, MHRA
    Where are We Headed with Evidence of Effectiveness: A European Regulatory Perspective
  129. Robert Lionberger, PhD, US Food and Drug Administration
  130. Robert Temple, MD, US Food and Drug Administration
    Where Are We Headed with Evidence of Effectiveness: A Regulatory Perspective
  131. Russ Altman, MD, PhD, Stanford University
    Presenting Your Work So That People Remember It
  132. Sandhya Girish, Ph.D, Genentech
  133. Sarah Schrieber, Pharm.D, FDA
    Regulatory Experience on Approval of ADCs
  134. Scott Waldman, MD, PhD, Thomas Jefferson University
    Successful Abstracts
  135. Sean Hennessy, PharmD, PhD, University of Pennsylvania
    Pharmacoepidemiology: The Study of Drugs in Populations
  136. Sebastian Polak, PhD, Simcyp
    Physiologically-Based Cardiomyocyte Model: Predicting QT Changes in Humans
  137. Sharon Straus, MD, MSc FRCPC, Li Ka Shing Knowledge Institute of St. MichaelÕs and the University of Toronto
  138. Sheldon Preskorn, MD, University of Kansas Medical Center
    Psychiatry: Clinical Pharmacology of Antipsychotics and Antidepressants
  139. Shiew-Mei Huang, PhD, US Food and Drug Administration
    Drug Interactions: An Evolution in Drug Development
  140. Sony Tuteja, PharmD, University of Pennsylvania
  141. Sook Wah Yee, Ph.D., University of California San Francisco
  142. Sreeneeranj Kasichayanula, PhD, Amgen
  143. Srijib Goswami, BS, University of California
  144. Stacy Shord, PharmD, FCCP, BCOP, US Food and Drug Administration
  145. Stephan Schaller, PhD, Bayer Technology Services GmbH
  146. Steve Ryder, MD, FACP, Alexion Pharmaceuticals
  147. Steven Kern, PhD, Bill & Melinda Gates Foundation
    The Big 3: Using Clinical Pharmacology and Epidemiologic Modeling as Tools to Achieve Global Control or Eradication of TB, HIV and Malaria
  148. Steven Riley, PharmD, PhD, Pfizer, Inc
  149. Suzanne Topalian, MD, Johns Hopkins University
  150. Tae Han, Ph.D, Stem CentRx, Inc.
    Overview of Clinical Pharmacology Plan for ADCs
  151. Tanay Samant, Ph.D., University of Florida
  152. Tarek Leil, , Bristol-Myers Squibb
  153. Tatiana Karelina, PhD, Institute for Systems Biology
  154. Tatiana Yakovleva, MS, Institute for Systems Biology Moscow
  155. Ted Grasela, PharmD, PhD, Simulations Plus, Inc.
  156. Thaddeus Grasela, PhD, Simulaitons Plus, Inc/ Cognigen Corporation
  157. Thomas Ludden, PhD, ICON Development Solutions
    Contributions to Applied Pharmacometrics
  158. Veronika Voronova, MS, Institute for Systems Biology SPb
  159. Vikram Sinha, PhD, US Food and Drug Administration
    Role of Clinical Pharmacology in Developing Evidence of Effectiveness
  160. Virginia (Ginny) Schmith, PhD, FCP, Nuventra Pharma Sciences
  161. Vivek Purohit, PhD, Pfizer
  162. Wendy (Ankrom) Comisar, PhD, Merck & Co., Inc
    Biomarkers and Beyond: Translating from the Clinic to the Lab and Back Again
  163. Wendy Comisar, PhD, Merck & Co., Inc
  164. William Evans, PharmD, St. Jude Children's Research Hospital
  165. William Thompson, Ph.D., Pfizer
  166. Xiaochen Zhao, , University at Buffalo
  167. Xiaomin Liang, Bachelor of Science, University of California, San Francisco
  168. Xiaoping Zhang, PhD, Kyowa Hakko Kirin Pharma Inc.
  169. Xin-Ning Yang, PhD, Food and Drug Administration
  170. Xinyuan Zhang, Ph.D., US Food and Drug Administration
  171. Yan Feng, PhD, Bristol-Myers Squibb
  172. Yang-Yu Liu, PhD, Harvard Medical School
    Observability of Complex Systems
  173. Yong Huang, Ph.D., Optivia Biotechnology Inc.
  174. Yvonne Lau, PhD, Novartis Pharmaceuticals Corporation
    CERITINIB: BREAKTHROUGH TREATMENT FOR ALK-POSITIVE NON-SMALL CELL LUNG CANCER